Denali Therapeutics (DNLI) Competitors $14.93 -0.26 (-1.71%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. ROIV, RVMD, VRNA, BBIO, ELAN, GRFS, TLX, TGTX, NUVL, and LEGNShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Roivant Sciences Revolution Medicines Verona Pharma BridgeBio Pharma Elanco Animal Health Grifols Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Nuvalent Legend Biotech Roivant Sciences (NASDAQ:ROIV) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations. Do insiders and institutionals hold more shares of ROIV or DNLI? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is ROIV or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Denali Therapeutics N/A -32.94%-30.04% Which has more volatility & risk, ROIV or DNLI? Roivant Sciences has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Does the MarketBeat Community favor ROIV or DNLI? Denali Therapeutics received 415 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.87% of users gave Roivant Sciences an outperform vote while only 68.76% of users gave Denali Therapeutics an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5678.87% Underperform Votes1521.13% Denali TherapeuticsOutperform Votes47168.76% Underperform Votes21431.24% Do analysts recommend ROIV or DNLI? Roivant Sciences presently has a consensus price target of $17.50, suggesting a potential upside of 52.57%. Denali Therapeutics has a consensus price target of $33.71, suggesting a potential upside of 125.82%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06 Which has higher valuation and earnings, ROIV or DNLI? Roivant Sciences has higher earnings, but lower revenue than Denali Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$29.05M268.38$4.35B-$0.25-45.88Denali Therapeutics$330.53M6.56-$145.22M-$2.67-5.59 Does the media prefer ROIV or DNLI? In the previous week, Roivant Sciences had 4 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Roivant Sciences and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.41 beat Roivant Sciences' score of 0.44 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDenali Therapeutics beats Roivant Sciences on 12 of the 19 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.17B$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-5.4132.9027.1719.96Price / Sales6.56466.20410.96157.63Price / CashN/A168.6838.2534.64Price / Book2.013.427.064.69Net Income-$145.22M-$72.35M$3.23B$248.14M7 Day Performance1.56%3.01%0.77%0.95%1 Month Performance4.70%20.80%9.67%5.74%1 Year Performance-32.50%-17.10%32.02%14.73% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.3529 of 5 stars$14.93-1.7%$33.71+125.8%-30.7%$2.17B$330.53M-5.41430Positive NewsAnalyst RevisionROIVRoivant Sciences2.4073 of 5 stars$11.17+1.6%$17.50+56.7%+5.9%$7.97B$29.05M-74.46860RVMDRevolution Medicines4.4546 of 5 stars$40.65+3.2%$67.08+65.0%+2.8%$7.57B$742K-11.32250Positive NewsVRNAVerona Pharma2.1857 of 5 stars$84.10+3.6%$82.13-2.3%+527.1%$6.82B$118.54M-43.8030Positive NewsAnalyst ForecastAnalyst RevisionBBIOBridgeBio Pharma4.5684 of 5 stars$35.46+3.5%$57.09+61.0%+38.2%$6.73B$127.42M-12.44400Trending NewsInsider TradeAnalyst RevisionELANElanco Animal Health1.0644 of 5 stars$13.440.0%$15.17+12.9%-20.6%$6.67B$4.43B33.599,800GRFSGrifols3.8381 of 5 stars$8.30-0.1%N/A+27.7%$5.71B$7.21B7.0926,300Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.80-1.1%$22.00+31.0%N/A$5.68B$783.21M0.00N/ANews CoverageAnalyst ForecastTGTXTG Therapeutics2.9523 of 5 stars$35.75+1.8%$40.80+14.1%+122.3%$5.68B$386.39M-357.46290Analyst RevisionNUVLNuvalent2.5787 of 5 stars$77.18+3.4%$115.50+49.7%-2.6%$5.54BN/A-22.2440Positive NewsLEGNLegend Biotech3.0777 of 5 stars$29.32+1.3%$76.20+159.9%-17.1%$5.39B$728.30M-30.861,070Short Interest ↑Analyst Revision Related Companies and Tools Related Companies Roivant Sciences Competitors Revolution Medicines Competitors Verona Pharma Competitors BridgeBio Pharma Competitors Elanco Animal Health Competitors Grifols Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors TG Therapeutics Competitors Nuvalent Competitors Legend Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
